CTMX — CytomX Therapeutics Share News
0.000.00%
Last trade - 00:00- $531.67m
- $201.39m
- $76.20m
CytomX Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
CytomX Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
CytomX Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
CytomX Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: CytomX Therapeutics Names Chris Ogden As Chief Financial Officer
U.S. STOCKS ON THE MOVE-Hilton Grand Vacations, natgas firms, Silvaco
U.S. STOCKS ON THE MOVE-Gold miners, Energy Transfer, Aercap
U.S. STOCKS ON THE MOVE-Plug Power, Cheesecake Factory, HubSpot
U.S. STOCKS ON THE MOVE-Exact Sciences, Sezzle, Robinhood Markets
CytomX Therapeutics slides on questions over cancer therapy's trial data
Brief: Cytomx Therapeutics Announces Positive Initial Phase 1A Dose Escalation Data For Monotherapy Cx-904
CytomX Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: CytomX Therapeutics Announces First Patient Dosed With CX-2051 In Phase 1 Study In Patients With Advanced Solid Tumors
Brief: CytomX Therapeutics Announces Nomination Of Second Clinical Candidate In Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration With Astellas
Brief: CytomX Therapeutics Announces Milestone Achievement In PROBODY® T-Cell Engaging Bispecific Collaboration With Astellas
Brief: Cytomx Therapeutics Inc Cash, Cash Equivalents And Investments Totaled $174.5 Million As Of December 31, 2023
CytomX Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
CytomX Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Cytomx Therapeutics Announces FDA Clearance Of Ind Applications For Cx-2051, A Probody® Antibody Drug Conjugate (Adc) Targeting Epcam And Cx-801, A Conditionally Activated Interferon Alpha-2B